Zobrazeno 1 - 10 of 77 pro vyhledávání: '"R. Brian Mitchell"'
2
Abstract 662: Longitudinal blood-based proteomic testing in advanced non-small cell lung cancer
Autor: Wallace Akerley, Ray D. Page, R. Brian Mitchell, Kan Huang, Mitchell Haut, Jason Keith Boyd, J. Dubay, Nagaprasad Nagajothi, Savita Bidyasar, J. Orsini, Mazen Khalil, Eric Scott Schaefer
Publikováno v: Cancer Research. 81:662-662
Motivation. A blood-based proteomic host immune classifier (HIC) that identifies a patient's disease state as Hot or Cold can aid prognostication and help guide treatment decisions in non-small cell lung cancer (NSCLC). The HIC Hot label is associate
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::687c260de6c5bd822951b4f92782d22d
https://doi.org/10.1158/1538-7445.am2021-662
Zobrazit plný text záznamu
3
Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer
Autor: D. Oubre, R. Brian Mitchell, J. Orsini, Edgardo S. Santos, Patricia Rich, Scott Boniol, Warren Brenner, Jonathan Goldberg, Waseemullah Khan, Suman Sinha, Savita Bidyasar, Eric Scott Schaefer, Emily K. Pauli, Paul R. Walker, Kan Huang, Andrea Veatch, Linda Traylor, Maria Quejada, Wallace Akerley, Mitchell Haut, Mazen Khalil, Bassam Ghabach, Ray D. Page, Hafez Halawani, Jason Keith Boyd, J. Dubay
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for Immunotherapy of Cancer
PurposeImmune checkpoint inhibition (ICI) therapy has improved patient outcomes in advanced non-small cell lung cancer (NSCLC), but better biomarkers are needed. A clinically validated, blood-based proteomic test, or host immune classifier (HIC), was
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3604c791c5637fc3d7b0dbb8a428d9a
https://doi.org/10.1136/jitc-2021-002989
Zobrazit plný text záznamu
5
Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer
Autor: David M. Waterhouse, Jeffrey Zangmeister, David R. Spigel, Howard A. Burris, J. David Bass, F. Anthony Greco, Davey B. Daniel, Elke K. Friedman, Dianna Shipley, R. Brian Mitchell, Robert C. Whorf, John D. Hainsworth
Publikováno v: Journal of Clinical Oncology. 29:2582-2589
Purpose Sorafenib, an oral multikinase inhibitor, has shown preliminary activity in non–small-cell lung cancer (NSCLC). Patients with advanced NSCLC were treated with erlotinib with or without sorafenib in this multicenter phase II trial. Patients
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::653b118beb0e6117c728b122c4794f73
https://doi.org/10.1200/jco.2010.30.7678
Zobrazit plný text záznamu
6
American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants
Autor: Todd H. Wasserman, Karen L. Hagerty, Martee L. Hensley, Neal J. Meropol, Gary I. Cohen, Daniel M. Green, William J. Gradishar, Andy Trotti, Daniel D. Von Hoff, Bahman Emami, R. Brian Mitchell, Tarun Kewalramani, Lynn M. Schuchter, J. Tate Thigpen
Publikováno v: Journal of Clinical Oncology. 27:127-145
Purpose To update a clinical practice guideline on the use of chemotherapy and radiation therapy protectants for patients with cancer. Methods An update committee reviewed literature published since the last guideline update in 2002. Results Thirty-n
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdd744623651aa7c52bcdab7fb8333c9
https://doi.org/10.1200/jco.2008.17.2627
Zobrazit plný text záznamu
7
American Society of Clinical Oncology Clinical Practice Guidelinesfor the Use of Chemotherapy and Radiotherapy Protectants
Autor: William J. Gradishar, Martee L. Hensley, Gary I. Cohen, Neal J. Meropol, Todd H. Wasserman, Robert S. Negrin, J. Tate Thigpen, R. Brian Mitchell, Robert J. Langdon, Daniel M. Green, Ted P. Szatrowski, Celeste Lindley, Daniel D. VonHoff, Lynn M. Schuchter, Gail Broder, Eric P. Winer, David G. Pfister
Publikováno v: Journal of Clinical Oncology. 17:3333-3355
PURPOSE:Because toxicities associated with chemotherapy and radiotherapy canadversely affect short- and long-term patient quality of life, can limitthe dose and duration of treatment, and may be life-threatening, specificagents designed to ameliorate
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1752221e2d82b78da1eda02fa45c5a87
https://doi.org/10.1200/jco.1999.17.10.3333
Zobrazit plný text záznamu
8
Sequential therapy with dacarbazine and carmustine: a phase I study
Autor: Richard L. Schilsky, M. Eileen Dolan, Mark J. Ratain, R. Brian Mitchell, Linda Janisch, Nicholas J. Vogelzang
Publikováno v: Cancer Chemotherapy and Pharmacology. 34:509-514
Depletion of the DNA-repair protein O6-alkylguanine-DNA alkyltransferase (AGT) increases the sensitivity of cells in culture and of human tumor xenografts to chloroethylnitrosoureas such as carmustine (BCNU). We have previously demonstrated that daca
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03ad2acb21cbd9dc6c1947ef1a1458e6
https://doi.org/10.1007/bf00685663
Zobrazit plný text záznamu
9
Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea
Autor: R. Brian Mitchell, M. Eileen Dolan
Publikováno v: Cancer Chemotherapy and Pharmacology. 32:59-63
We investigated the ability of 5-(dimethyltriazeno)imidazole-4-carboxamide (DTIC, decarbazine) and an analogue, temozolomide, to deplete cells or tumors of O6-alkylguanine-DNA alkyltransferase (AGT) and to enhance the antitumor effects of 1,3-bis(2-c
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddab461835a320098893f4fad0429c85
https://doi.org/10.1007/bf00685877
Zobrazit plný text záznamu
10
Phase II trial of preoperative carboplatin (carbo)/pemetrexed (pem) in patients (pts) with select stage IB-IIIA nonsquamous non-small cell lung cancer (NS-NSCLC)
Autor: Donald C. Townsend, David Michael Waterhouse, F. Anthony Greco, R. Brian Mitchell, Victor M. Priego, Fred J. Kudrik, Howard A. Burris, Michael McCleod, David R. Spigel, John D. Hainsworth, Ralph V. Boccia, Kent C. Shih
Publikováno v: Journal of Clinical Oncology. 32:e18510-e18510
e18510 Background: Adjuvant platinum-based chemotherapy is standard treatment (tx) in select early stage NSCLC. Adjuvant cisplatin/pem was safe, less toxic, and easier to deliver than vinorelbine/cisplatin in a randomized phase II trial (Kreuter Ann
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::216ded148cbedf7c95a516c72bbfc182
https://doi.org/10.1200/jco.2014.32.15_suppl.e18510
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje